Literature DB >> 12607644

Limited operation for severe multisegmental bilateral bronchiectasis.

Julien Mazières1, Marléne Murris, Alain Didier, Jacques Giron, Marcel Dahan, Jean Berjaud, Paul Léophonte.   

Abstract

BACKGROUND: Some patients exhibiting severe multisegmental bilateral bronchiectasis are no longer improved with antibiotic treatment and drainage and, most of the time, operation is contraindicated. In our institution, limited operation has been offered to select patients for this indication. We report our data regarding the feasibility and utility of such a procedure.
METHODS: We studied 16 patients who underwent surgical removal of nonlocalized disease between 1990 and 1999. We report the mortality and morbidity rates of this surgical procedure and the clinical, bacteriological, and functional data for each patient.
RESULTS: There was no mortality and the morbidity was low (18%, all with favorable outcome). Symptoms such as hemoptysis, sputum production, or dyspnea were also improved. The recurring infections decreased in frequency in 8 patients and disappeared completely in 5 others. The bacteriological data assessment revealed disappearance of germs in 4 patients and persistence of chronic colonization in others. Postoperative spirometric data were not worsened and postoperative computed tomographic scans did not show progression of lesions not removed.
CONCLUSIONS: These results suggest that, in properly selected patients, lasting symptomatic improvement can be achieved by resection. Limited operation may be indicated in nonlocalized bilateral bronchiectasis, provided that a target can be identified. This procedure is supported by physiopathologic arguments and is particularly relevant to patients with bronchiectasis with cystic and functionless territories.

Entities:  

Mesh:

Year:  2003        PMID: 12607644     DOI: 10.1016/s0003-4975(02)04322-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  A long-term study assessing the factors influencing survival and morbidity in the surgical management of bronchiectasis.

Authors:  Abidin Sehitogullari; Salim Bilici; Fuat Sayir; Ufuk Cobanoglu; Ali Kahraman
Journal:  J Cardiothorac Surg       Date:  2011-12-11       Impact factor: 1.637

2.  The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis.

Authors:  Hamdan Al-Jahdali; Abdullah Alshimemeri; Abdullah Mobeireek; Amr S Albanna; Nehad N Al Shirawi; Siraj Wali; Khaled Alkattan; Abdulrahman A Alrajhi; Khalid Mobaireek; Hassan S Alorainy; Mohamed S Al-Hajjaj; Anne B Chang; Stefano Aliberti
Journal:  Ann Thorac Med       Date:  2017 Jul-Sep       Impact factor: 2.219

3.  Uniportal thoracoscopic treatment in bronchiectasis patients: preliminary experience.

Authors:  Ilhan Ocakcioglu
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-10-15       Impact factor: 1.195

4.  Surgical treatment of bronchiectasis: Our 23 years of experience.

Authors:  Selim Şakir Erkmen Gülhan; Leyla Nesrin Acar; Ebru Sayılır Güven; Pınar Bıçakçıoğlu; Ertan Aydın; Sezgin Karasu; Abdullah İrfan Taştepe; Funda İncekara; Sadi Kaya; Göktürk Fındık
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-10-21       Impact factor: 0.332

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.